Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Randomized Controlled Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Eur J Clin Pharmacol1
Search Results
Sort by
- Bookvolume editors, Lluís Puig, Wayne Gulliver.Contents:
Adverse reactions to biologics in psoriasis / Lockwood, S.J., Prens, L.M.; Kimball, A.B.
Clinical trial and registry data / Gooderham, M., Papp, K.
Immunosuppression/infections across indications / Al-Khalili, A., Dutz, J.P.
The immunogenicity of biologic therapies / Garcias, S., Demengeot, J.
Paradoxical reaction S : anti-tumor necrosis factor alpha agents, Ustekinumab, Secukinumab, Ixekizumab, and others / Puig, L.
Bullous diseases / Corbaux, C., Joly, P.
Adverse reactions of antibody-therapy for primary cutaneous lymphomas : Rituximab, Brentuximab vedotin, Alemtuzumab, and Mogamulizumab / Saulite, I., Guenova, E., Hoetzenecker, W.
Adverse reactions to biologics : melanoma (Ipilimumab, Nivolumab, Pembrolizumab) / Hwang, S.J.E., Fernández-Peñas, P.
Skin manifestations of targeted antineoplastic therapy / Sanmartín, O.Digital Access Karger 2018 - ArticleHansson L, Berglund G, Andersson O, Holm M.Eur J Clin Pharmacol. 1977 Oct 14;12(2):89-92.Acebutolol, a new cardioselective beta-adrenoceptor blocking agent, has been evaluated for the treatment of hypertension. Thirty eight previously untreated male patients with essential hypertension received placebo treatment during a 4-week run-in period, and then they were randomly (double-bind) allocated either to continued placebo treatment for three 4-week periods or to treatment with acebutolol 400, 600, and 1200 mg daily, respectively, for three 4-week periods. Blood pressure and heart rate were recorded at the end of each 4-week period. Treatment with acebutolol produced statistically significant reductions in blood pressure and heart rate as compared to the placebo regimen.